Top Page
Dr. Martens Plc
(LSE:DOCS)
Dr. Martens Plc (DOCS) vs. iShares MSCI United Kingdom ETF (EWC)
Dr. Martens Plc Business Overview & Revenue Model
Dr. Martens Plc Earnings Call Summary
Dr. Martens Plc Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 785.00M | 787.60M | 877.10M | 1.00B | 908.30M | 773.00M |
| Gross Profit | 479.70M | 511.70M | 575.20M | 618.10M | 578.80M | 470.50M |
| EBITDA | 152.70M | 110.50M | 196.30M | 235.00M | 265.10M | 143.30M |
| Net Income | 15.30M | 4.50M | 69.20M | 128.90M | 181.20M | 34.70M |
Balance Sheet | ||||||
| Total Assets | 865.40M | 889.80M | 952.40M | 992.60M | 859.10M | 652.80M |
| Cash, Cash Equivalents and Short-Term Investments | 95.70M | 155.90M | 111.10M | 157.50M | 228.00M | 113.60M |
| Total Debt | 397.10M | 404.10M | 477.00M | 451.80M | 393.80M | 366.40M |
| Total Liabilities | 536.30M | 523.40M | 584.20M | 588.40M | 530.90M | 502.10M |
| Stockholders Equity | 329.10M | 366.40M | 368.20M | 404.20M | 328.20M | 150.70M |
Cash Flow | ||||||
| Free Cash Flow | 118.00M | 177.60M | 139.50M | 25.90M | 159.40M | 99.50M |
| Operating Cash Flow | 126.40M | 196.30M | 167.90M | 77.30M | 184.40M | 121.40M |
| Investing Cash Flow | -14.00M | -15.30M | -25.50M | -50.60M | -25.00M | -21.90M |
| Financing Cash Flow | -110.50M | -134.20M | -185.90M | -99.50M | -47.00M | -44.00M |
Dr. Martens Plc Technical Analysis
Dr. Martens Plc Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | £15.41B | 19.77 | 51.86% | 1.80% | 9.74% | 0.92% | |
71 Outperform | £4.05B | 8.28 | 19.64% | 1.21% | 14.60% | 58.84% | |
64 Neutral | £650.99M | 42.09 | 4.61% | 3.36% | -2.59% | -46.13% | |
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
59 Neutral | £394.75M | -1.32 | -81.34% | ― | -14.89% | 12.08% | |
55 Neutral | £3.94B | -145.76 | -3.00% | ― | -9.44% | -170.53% | |
54 Neutral | £24.27M | 12.87 | 8.50% | ― | -6.24% | -82.21% |
Dr. Martens Plc Corporate Events
Dr. Martens plc has confirmed that, as of 30 January 2026, its issued ordinary share capital stands at 967,319,559 shares, each carrying one voting right, with no shares held in treasury. This updated total voting rights figure provides the formal denominator that investors must use when calculating whether they need to disclose new or changed holdings under UK transparency rules, clarifying the company’s current equity base for shareholders and market participants.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £72.00 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.
Dr. Martens plc has instructed the trustee of its Employee Benefit Trust to purchase up to 10 million of the company’s ordinary shares on the open market, to be held on an unallocated basis for use in meeting current and future obligations under its employee share plans. The move underlines the group’s ongoing commitment to equity-based remuneration and could modestly tighten the available free float, while providing flexibility in incentivising staff across its global operations without immediately issuing new shares.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £66.00 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.
Dr. Martens reported a modest decline in third-quarter group revenue as it pushed ahead with a “consumer-first” turnaround that prioritises full-price sales over discounting, particularly in ecommerce. For the 13 weeks to 28 December 2025, revenue fell 2.7% at constant currency to £253m, with direct-to-consumer sales down 6.5% and wholesale up 9.5%, reflecting a deliberate pullback from clearance activity and a tougher consumer backdrop, especially in EMEA where DTC revenue slumped 12% while wholesale grew 13%. The Americas delivered 2% revenue growth, driven by stronger retail and a more disciplined wholesale mix, and APAC saw a small overall decline as reduced promotions hit DTC but boosted full-price performance, with South Korea continuing to grow strongly. Management said it is on track to deliver all four strategic objectives for FY26, including reducing reliance on discounted wholesale in the US, expanding newer product families, opening new markets via capital-light partnerships—such as an expanded Latin American distribution deal—and simplifying its operating model to be closer to local consumers. Despite expecting broadly flat constant-currency revenue for FY26 as it prioritises profitability and revenue quality, Dr. Martens reiterated guidance for significant year-on-year growth in profit before tax, though it warned that foreign exchange volatility now implies a larger revenue headwind and a broadly neutral effect on adjusted PBT.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £100.00 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.
Dr. Martens has disclosed that chief executive officer Ije Nwokorie and chief financial officer Giles Wilson have each acquired 192 ordinary shares in the company through the firm’s HMRC-approved all-employee Share Incentive Plan, at a price of 77.894 pence per share. Under the same plan, both executives were also granted 192 matching shares for no consideration, underscoring ongoing senior management participation in the company’s equity-based remuneration scheme and aligning leadership incentives more closely with shareholder interests.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £100.00 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.
Dr. Martens plc has confirmed that, as of 31 December 2025, its issued ordinary share capital comprises 967,295,505 shares of GBP 0.01 each, all of which carry one voting right and none of which are held in treasury. This disclosure formalises the total number of voting shares in issue, providing investors with the denominator needed to assess and report significant shareholdings under UK transparency rules, and thereby supports regulatory compliance and clearer visibility over the company’s ownership structure.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £84.00 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.
Dr. Martens Plc announced that its directors and persons discharging managerial responsibility participated in the company’s Share Incentive Plan (SIP), acquiring Partnership Shares and receiving Matching Shares. This move reflects the company’s commitment to employee engagement and aligns the interests of its management with those of its shareholders, potentially strengthening its market position and stakeholder relations.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £84.00 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.
Dr. Martens plc announced that Robert Hanson, an Independent Non-Executive Director, purchased 104,000 ordinary shares at a price of £0.7695 per share on the London Stock Exchange. This transaction reflects confidence in the company’s future prospects and may influence investor sentiment positively, highlighting the director’s commitment to the company’s growth and stability.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £84.00 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.
Dr. Martens plc announced that Robert Hanson, an Independent Non-Executive Director, purchased 96,000 ordinary shares at a price of £0.7886 each on December 5, 2025. This transaction, conducted on the London Stock Exchange, reflects a significant investment by a key company figure, potentially signaling confidence in the company’s future prospects and impacting stakeholder perceptions.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £84.00 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.
Dr. Martens has reported a 6% growth in full-price direct-to-consumer revenue, aligning with its shift to a consumer-first strategy. The company is seeing positive results from its new product launches and strategic growth initiatives, despite a challenging market environment. Financially, Dr. Martens has improved its performance, reducing net bank debt and maintaining strong cash flow. The Americas region performed best, while EMEA faced challenges. The company is focused on mitigating the impact of increased USA tariffs and expects to manage these effectively for future fiscal years.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £100.00 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.
Dr. Martens Plc announced a transaction involving its Share Incentive Plan (SIP), where directors Ije Nwokorie and Giles Wilson acquired Partnership Shares and were awarded Matching Shares. This move reflects the company’s commitment to employee investment and may enhance stakeholder confidence in its governance practices.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £100.00 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.